Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zapping stomach tumors with calcium: a new way to stop bleeding?

NCT ID NCT07647731

Disease control Sponsor: Hospital del Rio Hortega Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a procedure called calcium electroporation to stop bleeding from stomach cancer tumors. Doctors inject calcium into the tumor and use a special device to deliver small electrical pulses, which can help control bleeding. The trial will include 28 patients with advanced stomach cancer who have limited treatment options, and the goal is to see if the procedure safely reduces or stops bleeding.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
calcium gluconate
What this could lead to
If it works, this could offer a minimally invasive way to control tumor bleeding and improve quality of life for gastric cancer patients who cannot have surgery or strong treatments.
What could go wrong
This is a very early, small study (28 people) with no comparison group, so results may not apply broadly. The procedure may not stop bleeding or could cause side effects like pain or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 28 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants must meet all of the following criteria: * Age ≥18 years. * Histologically confirmed gastric malignancy. * Presence of anemia and/or gastrointestinal bleeding secondary to gastric cancer. * Ability and willingness to provide written informed consent. In addition, participants must meet at least one of the following conditions: * Patients considered unsuitable for surgical and/or oncological treatment with curative or palliative intent due to advanced age, frailty, or significant comorbidities (Charlson Comorbidity Index ≥3 and/or ECOG Performance Status ≥2), following multidisciplinary team assessment. * Patients with metastatic disease receiving palliative systemic therapy in whom CaEP is indicated for symptomatic control of tumor-related gastrointestinal bleeding. * Patients receiving neoadjuvant therapy who develop tumor-related gastrointestinal bleeding requiring bleeding control to avoid interruption of systemic treatment prior to surgery. * Patients who decline surgical and/or oncological treatment when CaEP is considered appropriate for symptomatic control of gastrointestinal bleeding. Exclusion Criteria: Participants meeting any of the following criteria will be excluded: * Pregnancy or breastfeeding. * Presence of an endoluminal prosthesis within the intended treatment area. * Implanted electrical devices (e.g., pacemakers, implantable cardioverter-defibrillators) when temporary deactivation is not feasible or procedural safety cannot be guaranteed. * Uncorrectable coagulation disorders. * Medical contraindication to deep sedation or therapeutic upper gastrointestinal endoscopy. * Estimated life expectancy of less than 1 month. * Refusal or inability to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Calcium electroporation for hemostasis in gastric neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric cancer gastric neoplasm Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Calcium electroporation for hemostasis in gastric neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.